12:00 AM
 | 
Oct 24, 2011
 |  BC Week In Review  |  Company News  |  Deals

miRagen, Santaris, Servier deal

Servier partnered with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 ( miR-208) and miR-15/195, as well as a cardiovascular microRNA modulator yet to be identified....

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >